Status and phase
Conditions
Treatments
About
BI 655064 will be administered subcutaneously once weekly in patients with immune thrombocytopenic purpura (ITP) for up to 12 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male and female chronic immune ITP patients
Exclusion criteria
Any treatment of ITP excluded except for a stable dose of corticosteroids (up to 20 mg)
Primary purpose
Allocation
Interventional model
Masking
6 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal